FTC: AbbVie's AndroGel litigation was a sham
The Federal Trade Commission yesterday told a federal judge that drugmaker AbbVie's patent lawsuits against two generic rivals were objectively baseless.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10